GlassScriptPhysician profile
Damanjit Ghuman
NPI 1649366832
$11,159.49
in general payments reported to CMS, 2019-2025
75 companies · $1,846 in 2025
The $1,846 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $1,363 · 2021: $2,108 · 2022: $1,742 · 2023: $775 · 2024: $1,777 · 2025: $1,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,383 · Education: $14.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,383.43 |
| Education | $14.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $886.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $832.82 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $818.19 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Amgen INC. | $565.22 | 2019-2025 | Evenity, Prolia, Tepezza |
| E.R. Squibb & Sons, L.L.C. | $556.78 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $494.75 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $474.04 | 2019-2025 | |
| Daiichi Sankyo INC. | $462.48 | 2020-2024 | Enhertu |
| Seagen INC. | $443.15 | 2019-2023 | Tukysa |
| Lilly USA, LLC | $319.84 | 2019-2025 | Jaypirca, Verzenio, Omvoh |
| Genzyme Corporation | $300.44 | 2019-2025 | |
| Astellas Pharma US INC | $276.57 | 2019-2023 | Padcev |
| Celgene Corporation | $256.08 | 2019-2025 | Reblozyl |
| Incyte Corporation | $250.86 | 2019-2025 | Jakafi |
| Exelixis INC. | $237.11 | 2019-2022 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damanjit Ghuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.